Literature DB >> 28593420

Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?

Hiroyuki Ito1, Haruhiko Nakayama2, Shuji Murakami3, Tomoyuki Yokose4, Kayoko Katayama5, Yoshihiro Miyata6, Morihito Okada6.   

Abstract

OBJECTIVES: We studied whether histologic subtype according to the new IASLC/ATS/ERS adenocarcinoma classification influences the extent of resection in patients with pathological stage IA lung adenocarcinoma.
METHODS: Data on 288 patients with pathological stage IA lung adenocarcinoma were analyzed retrospectively. Recurrence-free survival (RFS) rates were compared according to clinicopathological characteristics, including predominant histologic subtype and extent of resection.
RESULTS: Median follow-up was 38.9 months. Lobectomy was performed in 146 patients, and sublobar resection in 142 patients. When recurrence was compared among the low-grade group (adenocarcinoma in situ, AIS; minimally invasive adenocarcinoma, MIA), intermediate-grade group (lepidic, acinar, and papillary) and high-grade group (solid and micropapillary), the RFS rate decreased as the grade increased (p = 0.037). There was no recurrence in the low-grade or lepidic predominant groups. The recurrence pattern did not differ according to the type of resection or histological subtype. Even in the intermediate- and high-grade groups, the extent of resection was not significantly related to the RFS rate (p = 0.622, p = 0.516). The results were unchanged after adjusting for independent risk factors. The concordance rate between clinical and pathological stage IA was good in low (98.6%) and intermediate grade (84.6%) and poor in high grade (41.2%).
CONCLUSIONS: AIS, MIA, and lepidic predominant may be curable by any type of complete resection. Even in invasive subtypes, lobectomy does not offer a recurrence-free advantage over sublobar resection. However, in the high-grade group, less than half of clinical stage IA was actually pathological stage IA. Physicians should exercise caution whenever sublobar resection is planned.

Entities:  

Keywords:  Adenocarcinoma; Lung cancer; Pathological stage IA; Predominant subtype; Surgery

Mesh:

Year:  2017        PMID: 28593420     DOI: 10.1007/s11748-017-0790-0

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  22 in total

1.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L).

Authors:  Kenichi Nakamura; Hisashi Saji; Ryu Nakajima; Morihito Okada; Hisao Asamura; Taro Shibata; Shinichiro Nakamura; Hirohito Tada; Masahiro Tsuboi
Journal:  Jpn J Clin Oncol       Date:  2009-11-22       Impact factor: 3.019

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients.

Authors:  Junji Yoshida; Genichiro Ishii; Tomoyuki Yokose; Keiju Aokage; Tomoyuki Hishida; Mitsuyo Nishimura; Takuya Onuki; Masayuki Noguchi; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

4.  Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.

Authors:  Jung-Jyh Hung; Yi-Chen Yeh; Wen-Juei Jeng; Kou-Juey Wu; Biing-Shiun Huang; Yu-Chung Wu; Teh-Ying Chou; Wen-Hu Hsu
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

5.  Prospective study of extended segmentectomy for small lung tumors: the final report.

Authors:  Koichi Yoshikawa; Noriaki Tsubota; Ken Kodama; Hiroyoshi Ayabe; Toshihiko Taki; Takashi Mori
Journal:  Ann Thorac Surg       Date:  2002-04       Impact factor: 4.330

6.  Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.

Authors:  Valerie W Rusch; Debra Hawes; Paul A Decker; Sue Ellen Martin; Andrea Abati; Rodney J Landreneau; G Alexander Patterson; Richard I Inculet; David R Jones; Richard A Malthaner; Robbin G Cohen; Karla Ballman; Joe B Putnam; Richard J Cote
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.

Authors:  Jung-Jyh Hung; Wen-Juei Jeng; Teh-Ying Chou; Wen-Hu Hsu; Kou-Juey Wu; Biing-Shiun Huang; Yu-Chung Wu
Journal:  Ann Surg       Date:  2013-12       Impact factor: 12.969

9.  Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection.

Authors:  Yasuhiro Tsutani; Yoshihiro Miyata; Haruhiko Nakayama; Sakae Okumura; Shuji Adachi; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-09       Impact factor: 5.209

10.  Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer.

Authors:  Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Takehiko Shimoyama; Ryuta Suzuki
Journal:  J Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 5.209

View more
  7 in total

1.  Prediction of micropapillary and solid pattern in lung adenocarcinoma using radiomic values extracted from near-pure histopathological subtypes.

Authors:  Li-Wei Chen; Shun-Mao Yang; Hao-Jen Wang; Yi-Chang Chen; Mong-Wei Lin; Min-Shu Hsieh; Hsiang-Lin Song; Huan-Jang Ko; Chung-Ming Chen; Yeun-Chung Chang
Journal:  Eur Radiol       Date:  2021-01-03       Impact factor: 5.315

2.  Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography.

Authors:  Li-Wei Chen; Shun-Mao Yang; Ching-Chia Chuang; Hao-Jen Wang; Yi-Chang Chen; Mong-Wei Lin; Min-Shu Hsieh; Mara B Antonoff; Yeun-Chung Chang; Carol C Wu; Tinsu Pan; Chung-Ming Chen
Journal:  Ann Surg Oncol       Date:  2022-07-05       Impact factor: 4.339

3.  Prediction of the Invasiveness of Ground-Glass Nodules in Lung Adenocarcinoma by Radiomics Analysis Using High-Resolution Computed Tomography Imaging.

Authors:  Tianqi Zhang; Xiuling Li; Jianhua Liu
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

4.  Spiral wire localization of lung nodules: procedure effectiveness and oncological usefulness.

Authors:  Miriam Patella; Dario Alberto Bartolucci; Francesco Mongelli; Roberto Cartolari; Eleonora Maddalena Minerva; Rolf Inderbitzi; Stefano Cafarotti
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

5.  CEA-Ki-67- Pathologic Subtype: An Adjunct Factor for Refining Prognosis in Stage I Pulmonary Adenocarcinoma.

Authors:  Dongzhi Yu; Yanbin Sun; Michael A McNutt; Shun Xu
Journal:  Front Surg       Date:  2022-04-25

6.  The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.

Authors:  Hiroyuki Ito; Hiroshi Date; Yasushi Shintani; Etsuo Miyaoka; Ryoichi Nakanishi; Mitsutaka Kadokura; Shunsuke Endo; Masayuki Chida; Ichiro Yoshino; Hidemi Suzuki
Journal:  BMC Cancer       Date:  2022-08-10       Impact factor: 4.638

Review 7.  [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].

Authors:  Chen Shen; Wentao Fang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.